Home›Trial›NCT06697197
🔬NCT06697197Phase 1Phase 2RECRUITING

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Study Summary

The purpose of this study is to test the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.

Conditions
Advanced Solid Tumors
Interventions / Drugs
BMS-986482Nivolumab and rHuPH20Nivolumab/relatlimab/rHuPH20Bevacizumab
View on ClinicalTrials.gov ↗
Sponsor
BMY
Bristol-Myers Squibb
Oncology
F35/100
Study Details
Enrollment413 participants
Primary Completion—
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-04-11 04:08:14.746355+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.